These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 10782562)

  • 1. Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience.
    Velussi M; Cernigoi AM; Tortul C; Merni M
    Diabetes Nutr Metab; 1999 Dec; 12(6):407-12. PubMed ID: 10782562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
    Gentile S; Turco S; Guarino G; Sasso CF; Amodio M; Magliano P; Salvatore T; Corigliano G; Agrusta M; De Simone G; Gaeta I; Oliviero B; Torella R
    Diabetes Obes Metab; 2000 Dec; 2(6):355-62. PubMed ID: 11225965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.
    Hunninghake DB; Ballantyne CM; Maccubbin DL; Shah AK; Gumbiner B; Mitchel YB
    Clin Ther; 2003 Jun; 25(6):1670-86. PubMed ID: 12860491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
    Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Kontopoulos AG
    Diabetes Care; 2002 Jul; 25(7):1198-202. PubMed ID: 12087019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
    Diabetes Atorvastin Lipid Intervention (DALI) Study Group
    Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes.
    Wägner AM; Ordóñez-Llanos J; Jorba O; Pérez A
    Metabolism; 2004 Nov; 53(11):1516. PubMed ID: 15558848
    [No Abstract]   [Full Text] [Related]  

  • 9. The lipid-regulating effects of atorvastatin on type 2 elder diabetes patients with hyperlipidemia.
    Tu L; Liu X; Li R; Huang K; Yao H; Fan Q
    J Huazhong Univ Sci Technolog Med Sci; 2004; 24(2):138-9. PubMed ID: 15315163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
    Li XP; Duan J; Zhao SP; Tan MY; Xu ZM; Zhang DQ
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2399-403. PubMed ID: 17156651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
    Dart A; Jerums G; Nicholson G; d'Emden M; Hamilton-Craig I; Tallis G; Best J; West M; Sullivan D; Bracs P; Black D
    Am J Cardiol; 1997 Jul; 80(1):39-44. PubMed ID: 9205017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis.
    Hufnagel G; Michel C; Vrtovsnik F; Queffeulou G; Kossari N; Mignon F
    Nephrol Dial Transplant; 2000 May; 15(5):684-8. PubMed ID: 10809811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
    Davidson M; Ma P; Stein EA; Gotto AM; Raza A; Chitra R; Hutchinson H
    Am J Cardiol; 2002 Feb; 89(3):268-75. PubMed ID: 11809427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia.
    Branchi A; Fiorenza AM; Torri A; Muzio F; Berra C; Colombo E; Dalla Valle E; Rovellini A; Sommariva D
    Clin Ther; 2001 Jun; 23(6):851-7. PubMed ID: 11440285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia.
    Castaño G; Mas R; Fernández L; Illnait J; Mesa M; Alvarez E; Lezcay M
    Drugs Aging; 2003; 20(2):153-63. PubMed ID: 12534315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
    Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
    Amarenco P; Goldstein LB; Messig M; O'Neill BJ; Callahan A; Sillesen H; Hennerici MG; Zivin JA; Welch KM;
    Stroke; 2009 Jul; 40(7):2486-92. PubMed ID: 19461031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
    Athyros VG; Papageorgiou AA; Mercouris BR; Athyrou VV; Symeonidis AN; Basayannis EO; Demitriadis DS; Kontopoulos AG
    Curr Med Res Opin; 2002; 18(4):220-8. PubMed ID: 12201623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.